首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF11 |
| Uniprot No | O14788 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 152-317aa |
| 氨基酸序列 | LDLAKRSKLEAQPFAHLTINATDIPSGSHKVSLSSWYHDRGWAKISNMTF SNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPS SHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLDP DQDATYFGAFKVRDID |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF11(RANKL)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *Osteoprotegerin Ligand is a Cytokine that Regulates Osteoclast Differentiation and Activation*
**作者**: Lacey, D.L., et al.
**摘要**: 该研究首次克隆并表达了重组TNFSF11(即RANKL)，证实其通过结合RANK受体激活破骨细胞分化和骨吸收功能，揭示了其在骨代谢中的核心作用。
2. **文献名称**: *Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by Which OPG/OCIF Inhibits Osteoclastogenesis in Vitro*
**作者**: Yasuda, H., et al.
**摘要**: 通过重组蛋白实验，证明TNFSF11(RANKL)与其诱饵受体OPG的相互作用可阻断破骨细胞生成，为开发骨质疏松症治疗策略提供了分子机制基础。
3. **文献名称**: *RANK is the Essential Signaling Receptor for Osteoclast Differentiation in Osteoimmunology*
**作者**: Kong, Y.Y., et al.
**摘要**: 利用重组RANKL蛋白，揭示了RANKL-RANK信号轴在破骨细胞分化中的必要性，并证实该通路在炎症性骨病中的关键调控作用。
---
这些文献涵盖了TNFSF11重组蛋白的功能机制、受体互作及疾病治疗研究，均发表于*Nature*、*Cell*等高影响力期刊。如需更多细节，可进一步检索PubMed或Web of Science数据库。
**Background of TNFSF11 Recombinant Protein**
TNFSF11. also known as **Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)**, is a member of the tumor necrosis factor (TNF) superfamily. It plays a critical role in regulating bone metabolism, immune cell differentiation, and lymph node development. RANKL is primarily expressed by osteoblasts, stromal cells, and activated T cells, functioning as a transmembrane or soluble protein. Its interaction with the receptor RANK (expressed on osteoclast precursors and mature osteoclasts) activates downstream signaling pathways, including NF-κB and MAPK, which drive osteoclastogenesis and bone resorption. Dysregulation of RANKL signaling is linked to osteoporosis, rheumatoid arthritis, and cancer-induced bone destruction.
Recombinant TNFSF11 is engineered using biotechnological platforms (e.g., *E. coli* or mammalian expression systems*) to produce a purified, bioactive form of the protein. This recombinant protein typically retains the functional TNF homology domain, enabling *in vitro* and *in vivo* studies to dissect RANKL-mediated pathways or screen therapeutic agents. It is widely utilized in research to model bone diseases, study immune-bone crosstalk, and develop targeted therapies. For instance, anti-RANKL monoclonal antibodies (e.g., denosumab) have been clinically approved to treat osteoporosis and skeletal complications of malignancies.
Furthermore, recombinant TNFSF11 serves as a tool to explore its dual role in physiology and pathology, offering insights into potential applications in regenerative medicine, such as bone repair, and immunomodulation. Its standardized production ensures consistency in experimental and therapeutic contexts, bridging translational research and clinical innovation.
×
